Introduction of genes conferring drug resistance into hematopoietic cells may allow for improved chemotherapy by protection of normally drug-sensitive cells from the toxic side-effects of antitumor agents. We recently reported that transplantation of murine marrow transgenic for drug-resistant dihydrofolate reductase (DHFR) protected mice from lethal doses of methotrexate (MTX), demonstrating the feasibility of imparting drug resistance to recipients of marrow expressing drug-resistant DHFR activity. In order to optimize this strategy it is necessary to identify the hematopoietic cell populations which mediate drug resistance. For this purpose, we separated committed progenitor populations from primitive hematopoietic cells in DHFR transgenic marrow by counterflow elutriation (CE). As expected, supplementation with a fraction containing committed progenitors afforded protection from MTX-induced aplasia observed early after transplantion in animals administered MTX. In contrast, supplementation with a fraction containing primitive hematopoietic cells depleted of committed progenitors failed to provide immediate protection from early aplasia, but instead contributed to drug resistance 4 to 5 weeks after transplantation. The presence of primitive hematopoietic progenitors in both fractions was evident from Southern hybridization analysis for donor transgenic cells 2 months post-transplant. We conclude that protection from aplasia associated with MTX administration immediately after transplantation requires expression of drug-resistant DHFR activity in more differentiated, committed hematopoietic cells, while primitive DHFR transgenic progenitors contribute to longterm drug resistance. These results help to define the appropriate target cells for improved chemotherapy by protection of hematopoietic cells through the introduction of new genes conferring drug resistance.
Dihydrofolate reductase (DHFR) catalyzes the biosynthesis of tetrahydrofolate, which in turn serves as a one-carbon carrier required for the production of thymidylate and purines. 1 Since these compounds are required for DNA synthesis, the inhibition of DHFR activity results in arrest of cell division and replication. In actively dividing cells such as cancer cells, this inhibition ultimately results in cell death. For this reason inhibitors of DHFR activity, most notably methotrexate (MTX), have been successfully used as antineoplastic agents. 2 The inhibitory action of MTX that is the basis for its chemotherapeutic activity in tumor cells is also responsible for the side-effects observed in actively proliferating normal tissues. Although damage in the kidney, liver, respiratory mucosa, skin and reproductive organs has been observed after high doses of MTX, the primary sites of toxicity are the bone marrow and gastrointestinal (GI) tract, resulting in myelosuppression and breakdown of the mucosa. 3 These side-effects could potentially be mitigated by the expression of MTX-resistant DHFR in these tissues, rendering them less sensitive to MTX toxicity. Several mutants of DHFR have been shown to render cells resistant to MTX in vitro and in vivo. Most of the DHFR mutants which have been shown to be resistant to MTX contain mutations at either codons 22 or 31. [4] [5] [6] [7] [8] [9] [10] We have recently shown that transplantation of unfractionated transgenic marrow cells expressing either the arg22-DHFR or tyr22-DHFR mutants into lethally irradiated recipient mice confers resistance to two to three times the dose of MTX that is tolerated by normal mice. [11] [12] [13] These studies have demonstrated the feasibility of conferring MTX resistance to bone marrow transplant (BMT) recipients of whole marrow expressing drug-resistant DHFR activity. However, the hematopoietic cell populations responsible for conferring drug resistance in BMT recipients have not yet been characterized.
Jones et al 14, 15 demonstrated that primitive murine hematopoietic stem cells (HSC) contributing to long-term engraftment could be separated from more committed hematopoietic progenitor cells by counterflow elutriation (CE). They further showed that CE fractions containing HSC but depleted of more committed hematopoietic progenitors were incapable of rescuing animals from lethal total body irradiation (TBI), implying that more committed progenitors are necessary for hematologic function in the animals after lethal TBI but before stem cell recovery. Here we extend these studies by testing different CE fractions of 816 drug-resistant DHFR transgenic marrow for their ability to confer drug resistance when used to supplement unfractionated normal marrow transplanted into irradiated recipient animals. The results demonstrate that committed DHFR transgenic progenitors confer protection from MTX toxicity immediately post-transplant, while primitive DHFR hematopoietic progenitors confer long-term MTX resistance after engraftment. These results have important implications for the clinical application of drug-resistance gene transfer to protect normal hematopoietic cells from MTX toxicity, thus potentially allowing more effective use of MTX as an antitumor chemotherapeutic agent.
Materials and methods

Bone marrow fractionation
Generation and characterization of transgenic FVB/N mice expressing arg22-DHFR has been described by Morris et al. 16 Other transgenic FVB/N mice used in this study carry a 1.3 kb non-expressing 3Ј-untranslated region from a human amyloid precursor protein (APP) gene (gift from Dr K Hsiao, University of Minnesota). 17 Marrow was flushed from the hind limbs of either normal FVB/N, transgenic APP, or transgenic DHFR mice as previously described. 12 For CE, at least 2 × 10 8 nucleated cells were injected via a sampling site coupler into the inlet stream of a Beckman J6M/E centrifuge equipped with a JE-5.0 rotor (Beckman, Palo Alto, CA, USA). Cells were delivered at a flow rate of 15 ml/min, with the rotor speed at 900 g and the temperature at 25°C. After 100 ml of eluate were collected (fraction 15), the flow rate was increased stepwise to 25 ml/min, 29 ml/min, 30 ml/min and 35 ml/min, collecting 200 ml of eluate at each step and designating these as fractions 25, 29/30 (pool of eluates at flow rates 29 and 30 ml/min) and 35, respectively. The remaining cells were collected by turning the rotor off (R/O) and flushing the chamber with 100 ml of medium. Cells were washed and concentrated by centrifugation.
Hematopoietic colony assays
One and 5 × 10 4 cells from whole or fractionated marrow samples were plated in semi-solid medium containing 0.9% methylcellulose (Stem Cell Technologies, Vancouver, Canada), 30% newborn calf serum, 0.5% BSA, 0.1 mm ␤-mercaptoethanol, 10% WEHI-3-conditioned medium and 3 U/ml erythropoietin (R&D Systems, Minneapolis, MN, USA). Cultures were incubated at 37°C and 5% CO 2 in a humidified chamber for 2 weeks. Granulocyte-macrophage colonies containing more than 50 cells (CFU-GM) were scored microscopically on day 14.
Bone marrow transplant
Eight-week-old FVB/N mice were obtained from the NIH (Frederick, MD, USA) and provided food and water ad libitum. After 4 weeks (at age 12 weeks), recipient mice received 9 Gy total body irradiation from a 137 Cs source 1 day before transplant. Marrow cells (prepared as described above) were transplanted in 0.5 ml Iscove's modified Dulbecco's medium via the tail vein. The numbers and fractions of marrow cells injected are described in the 
Southern hybridization analysis
Sixty days post-transplant, marrow and spleen were harvested from surviving mice. Genomic DNA was isolated, digested with BglII and analyzed by Southern hybridization. 18 The DHFR probe used was a 485 bp PCR product that included exons 1 and 2 and intron 1 of the murine DHFR gene. 16 The murine Y probe was a 720 bp insert from plasmid pY2 (gift of Dr I Lemischka). 19 The 1.3 kb human APP probe was a gift from Dr K Hsiao. 17 Probes were labeled with 32 P by random priming (Oligolabelling Kit, Pharmacia, Piscataway, NJ, USA), and blots were hybridized and washed as previously described. 12 The resulting signals were quantitated using a 445SI PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA).
Results
Ability of CE fractions prepared from FVB/N marrow to rescue transplant recipients from lethal total body irradiation (TBI)
CE has previously been demonstrated to separate stem cells from committed progenitors in marrow populations from C57BL/6 mice 20 and C57BL/6 × DBA2 F 1 (B6D2F 1 ) mice. 14, 15 To verify the fractionation characteristics of hematopoietic cells from FVB/N mice, marrow was flushed from normal, non-transgenic animals and fractionated by CE as described in Materials and methods. The recovery of cells in each fraction (Table 1) was consistent with that shown previously for B6D2F 1 mice by Jones et al, 15 confirming the reproducibility of this procedure between mouse strains. The largest cell population was found in the R/O fraction (39%) while fraction 25, previously shown to contain HSC but to be deficient in committed progenitors, comprised about 12% of total cells. Colony-forming assays demonstrated that 85% of CFU-GM were present in the R/O fraction compared with only 0.02% in fraction 25.
To further characterize the cellular content of each mar- row fraction, their ability to support survival of transplant recipients was determined. Normal marrow cells from either fraction 25, R/O or both fractions were transplanted into lethally irradiated mice and survival was monitored. No mice survived when transplanted with fraction 25 cells, indicating that this fraction did not contain cells that could support hematopoiesis early after transplant ( Table 2 ). This was corroborated by the near absence of day 12 CFU-S in this fraction. The R/O fraction alone, however, conferred survival in two of five mice and contained 60% the level of CFU-S found in unfractionated cells. The combination of fraction 25 and R/O cells conferred survival in three of five mice, compared to unfractionated cells, which conferred survival in four of five mice. These results are consistent with the presence of cells in the R/O fraction capable of rescuing animals from aplasia after TBI. Fraction 25 was incapable of rescuing animals from aplasia immediately post-transplant due to a relative lack of cells capable of restoring hematopoiesis during this period of time.
Arg22-DHFR transgenic marrow fractions contributing to MTX resistance of bone marrow transplant recipients
To determine the minimum number of transgenic cells necessary to confer MTX resistance early after transplantation, between 0.1 and 2 × 10 6 transgenic R/O cells Mice used for survival assays were lethally irradiated and transplanted with 1 × 10 5 cells from each fraction of normal marrow as described in Materials and methods. The mice were allowed to recover for up to 60 days. Mice for CFU-S determination were transplanted with 2 × 10 expressing arg22-DHFR were transplanted into lethally irradiated recipients, followed by daily MTX administration at a final dose of 1 mg/kg bw. Only mice that were transplanted with at least 0.5 × 10 6 cells survived, indicating that the minimum dose of arg22-DHFR transgenic R/O cells required to confer MTX resistance is between 0.1 and 0.5 × 10 6 (Table 3) Table 3 . After 60 days of MTX administration at 1 mg/kg daily, surviving mice were sacrificed. DNA was extracted from bone marrow and subjected to Southern analysis using a DHFR probe as described in Materials and methods. The arrows indicate the positions of the endogenous and transgenic DHFR bands. Lethally irradiated FVB/N mice were transplanted with 1 × 10 6 normal FVB/N marrow cells alone or in combination with the indicated samples of fractionated or unfractionated arg22-DHFR transgenic marrow, followed by MTX administration at a final dose of 1 mg/kg bw as described in Materials and methods. The fraction of animals surviving at the end of each of the two experiments is shown for each group. each fraction by CE (Table 1 ) and the minimum number of R/O cells required to support survival in BMT recipients ( Table 3) . Transplant of 10 6 unfractionated, normal marrow (previously shown to be unable to confer long-term survival in mice receiving this MTX regimen 12 ) was necessary to support short-term survival of mice transplanted with fraction 25 marrow.
Animals not supplemented with DHFR transgenic cells suffered from severe anemia and death (1/10 surviving) after transplantation (Table 4 genic or R/O transgenic supplemented animals at 3 weeks post-transplant), similar to animals transplanted with nontransgenic, unfractionated marrow alone. In this experiment, fraction 25 recipients engrafted with primitive drugresistant progenitors early enough to allow recovery by 4 weeks after transplantation and a high survival rate (9/9 surviving).
Similar results were obtained in a second experiment conducted under identical conditions, except that female APP transgenics were used as a source of normal marrow. Again, MTX caused severe anemia in animals transplanted with unfractionated normal marrow alone (0/10 surviving), while animals supplemented with either whole DHFR transgenic marrow or the R/O fraction containing drug-resistant hematopoietic progenitors were largely protected from MTX toxicity (Table 4, Figure 2b) . As in the first experiment, animals supplemented with drug-resistant fraction 25 cells exhibited severe anemia for 2-3 weeks post-transplant (Figure 2b ; P Ͻ 0.001 vs animals supplemented with whole transgenic or R/O transgenic cells), but in this experiment engraftment of primitive drug-resistant progenitors did not occur early enough to rescue the animals from MTX toxicity (2/10 surviving). Thus, in both experiments we observed that drug-resistant cells obtained from the R/O fraction (containing committed progenitors) were required to protect animals from MTX toxicity immediately after transplantation, while fraction 25 cells were only capable of protecting animals from MTX toxicity several weeks (3 to 4) after transplantation.
Engraftment of donor cells in bone marrow transplant recipients
Mice that survived MTX administration for up to 60 days were sacrificed and the marrow and spleen harvested to determine the level of DHFR transgenic marrow engraftment by Southern analysis. Genomic DNA was analyzed using a DHFR probe to identify both the endogenous DHFR gene and the DHFR transgene, and either a Y or an APP probe was used to identify normal, co-transplanted marrow in experiments 1 and 2, respectively. In experiment 1, the spleens of mice transplanted with a combination of normal and arg22-DHFR transgenic cells contained both normal (Y-positive) and transgenic (DHFR transgene positive) cells after 60 days, with the exception of mouse number 6 which had an undetectable level of transgenic DHFR cells (Figure 3a) . Similarly, marrow harvested from surviving mice in experiment 2 contained both normal (Tg APP) and transgenic cells (Tg DHFR) in all groups ( Figure   N 4a). We conclude from these results that all transgenic donor samples (whole transgenic marrow, R/O, and fraction 25) contained primitive hematopoietic progenitors which contributed to transgenic cell engraftment in recipient animals 2 months post-transplant.
Discussion
Introduction of genes conferring drug resistance into hematopoietic cells may allow for improved chemotherapy by Table 4 ) were sacrificed 60 days posttransplant. Genomic DNA from bone marrow cells was subjected to Southern analysis as described in Materials and methods. DHFR and APP probes were used to quantitate total cells (En DHFR bands), transplanted transgenic DHFR cells (Tg DHFR bands) and transplanted normal cells (Tg APP bands). Control samples were from a normal mouse (N), transgenic DHFR mouse (D) and transgenic APP mouse (P). Signals were visualized using a Phosphorimager (a). Engraftment levels were quantitated as described in Figure 3 and are expressed as mean percent ± s.d. of 100% control samples for the groups that were transplanted with whole or R/O fraction of arg22-DHFR transgenic marrow (b). For mice 6 and 7 that were transplanted with arg22-DHFR transgenic fraction 25 marrow, individual values are shown.
protection of drug-sensitive, actively proliferating, normal cells from the toxic side-effects of potent antiproliferative agents such as MTX. Several drug resistance genes have been studied for this purpose, most notably the human multidrug resistance gene (MDR-1) 21 and MTX-resistant DHFR variants. 22 Clinical trials have been conducted to study the chemoprotective ability conferred by the MDR-1 gene when introduced into hematopoietic cells of breast cancer patients receiving chemotherapy. 23, 24 Several studies have demonstrated the feasibility of using retroviral vectors to transfer MTX-resistance genes into murine hematopoietic cells. Transplantation of cells retrovirally transduced with either the murine arg22-DHFR [25] [26] [27] or human ser31-DHFR 28 genes into mice conferred resistance of the recipients to MTX doses that are lethal to control mice. Successful transduction of hematopoietic stem cells was evidenced by protection from lethal MTX doses in serial transplant recipients as well. 25, 27 Animals can thus be rendered drug-resistant for an extended duration when they are engrafted with DHFR-transduced stem cells capable of maintaining hematopoiesis during MTX administration. The studies reported here aimed to characterize hematopoietic cell types (primitive progenitors as compared with more differentiated hematopoietic cell types) containing a MTX resistance gene that contributes to drug resistance in the recipient animal. We have recently reported transgenic mice expressing murine arg22, trp31 and tyr22 MTX-resistant DHFR variants, 11, 16 established on an FVB/N inbred background to allow syngeneic transplantion studies. Transplantation of whole marrow from donor FVB/N arg22 or tyr22 DHFR transgenics protected normal FVB/N recipient mice from lethal doses of MTX normally causing toxicity not only for hematopoietic cells but also for gastrointestinal tissues as well. 11, 12 Marrow from these transgenic animals thus provides a source of drug-resistant hematopoietic cells with which to investigate those cell types conferring drug resistance in recipient animals without the need for ex vivo culture or genetic manipulation prior to transplantation.
CE has previously been shown to separate HSC from more differentiated murine progenitor cells, such as spleen colony-forming cells and granulocyte-macrophage colonyforming cells. 15 It was demonstrated that HSC-containing fractions depleted of more committed progenitors were incapable of rescuing recipient mice from early aplasia after transplantation. Stem cell preparations relatively depleted of committed progenitors required supplementation with progenitors to allow survival of the recipient animals long enough for the HSC to engraft. In contrast, experiments have been reported in which a very small number of highly purified (Thy-1.1 lo Lin-Sca-1 + ) murine hematopoietic stem cells were demonstrated to rescue animals from lethal TBI. 29 These studies imply that HSC are capable of rapid differentiation and thus can contribute to hematopoiesis early after transplantation. In the current studies, we found that DHFR transgenic stem cell preparations depleted of committed progenitors (fraction 25), although capable of long-term engraftment and contribution to late hematopoiesis ( Figures 3 and 4) , did not protect animals from MTXassociated aplasia during the 2-week period of time immediately after transplantation. Rather, protection from MTX-associated aplasia required supplementation of the graft with the DHFR transgenic, drug-resistant progenitor fraction. These results demonstrate the need for more committed drug-resistant hematopoietic cell populations, supplied as part of the donor marrow, immediately after irradiation and BMT to support hematopoiesis long enough for engraftment of more primitive drug-resistant progenitors. It should be noted that the kinetics of repopulation for different hematopoietic compartments may be affected by MTX, as previously reported for the early recruitment of granulocytes under conditions of MTX administration. 30 Interestingly, administration of 1 mg/kg MTX for 60 days in these experiments was not sufficient to eliminate normal marrow cells when co-transplanted with arg22-DHFR transgenic cells, as determined by Southern analysis (Figures 3 and 4) . In fact, more than 20% of the cells in spleen and marrow of BMT recipients were donor-derived normal cells. This lack of a selective effect against normal hematopoietic cells has also been observed in animals administered MTX or trimetrexate at high doses for shorter periods of time. 31, 32 However, engrafted normal cells were incapable of conferring drug resistance on their own, and when transplanted without supplementation by MTX-resistant transgenic cells, the mice succumbed due to impaired hematopoiesis, as indicated by low hematocrit values ( Figure 2 ). It is most likely that MTX-resistant arg22-DHFR transgenic cells were able to support the survival of normal hematopoietic cells, and in separate experiments we have observed that donor marrow samples containing as little as 1% DHFR transgenic cells are sufficient to confer drug resistance in the recipient (James et al, manuscript in preparation).
Hematopoietic cells have been considered to be potentially effective targets for gene transfer in the treatment of cancer and inherited disorders. 33 Studies exploring this possibility have focused on HSC as targets for gene transfer, since successful transduction of HSC could provide genetically modified cell progeny of all hematopoietic lineages for the lifetime of the individual. We have found in this study, however, that expression in primitive progenitors of a DHFR gene conferring drug resistance does not protect animals from severe MTX-mediated myelosuppression immediately after transplantation. In order to protect animals from the immediate myelosuppressive effects of MTX, it is necessary to provide more differentiated cells expressing MTX-resistant DHFR activity. Thus, for the purpose of chemoprotection immediately after transplant it will be necessary to target gene transfer to more differentiated cells which are capable of restoring hematopoiesis during recovery from BMT, while more primitive cells must be targeted in order to mediate long-term MTX resistance. This distinction in drug-resistant hematopoietic cell populations and the timing of their effectiveness may prove to be useful in light of current difficulties associated with the low efficiency of gene transfer and stable expression of transduced genes in hematopoietic stem cells. 34 
